Eye Care

NK is a degenerative corneal disease resulting from diminished corneal innervation.

The regenerative medicine advanced therapy designation expedites the development and review of regenerative medications that have the potential to address unmet needs for serious or life-threatening diseases.

Successfully integrating biosimilars into practices requires careful planning and execution, as they impact virtually all aspects of a practice.

Dyslipidemia is a condition in which there are abnormal levels of lipids in the blood stream, including high levels of low-density lipoprotein cholesterol, low levels of high-density lipoprotein cholesterol, and/or high levels of triglycerides.

The study investigated faricimab-svoa (Vabysmo) as treatment of diabetic macular edema for patients in racial and ethnic groups that are often underrepresented in trials.

Treatment with valacyclovir for a year decreased the risk of new or worsening eye disease by 26%.

Digital eye strain is a common cause of dry, red, and itchy eyes.

Female and older patients had a greater incidence of herpes zoster ophthalmicus and were more likely to develop ocular complications.

In May 2024, the first biosimilars for aflibercept were approved, which included aflibercept-jbvf (Yesafili; Biocon Biologics), known as MYL-1701P.

The treatment is indicated to improve and maintain visual acuity in individuals with neovascular age-related macular degeneration.

Use of semaglutide injections may be linked to an increased risk of blindness in patients with diabetes.

Switching from aflibercept (Eylea; Regeneron Pharmaceuticals) to biosimilar ranibizumab (Lucentis; Genentech) for neovascular age-related macular degeneration could be more cost effective for patients.

Prevalence of dry eye is increasing drastically, especially in younger individuals, because of the current lifestyle and increased technology use.

Following the previous FDA approval of faricimab-svoa to treat some of the leading causes of vision loss, the Administration has approved a single-dose prefilled syringe of the drug which could lead to safer and more efficient administration while easing patient burden.

Caution Patients Against the Use of Redness-Reducing Eye Drops.

Aflibercept-jbvf (Yesafili; Biocon Biologics) and aflibercept-yszy (Opuviz; Biogen, Samsung Bioepis) are the first interchangeable biosimilars to aflibercept (Eylea; Regeneron).

In a review, investigators focused on ranibizumab (Lucentis; Genentech), aflibercept (Eylea; Regeneron), and bevacizumab (Avastin; Genentech) as growth opportunities in the biosimilar space.

Cardinal Health released its 2024 biosimilars report, including research and in-depth analyses on legislative development, payer landscapes, and new treatments in the pipeline.

Switching from adalimumab originator to SB5 did not cause clinically significant differences in treatment efficacy and safety for patients with noninfectious uveitis.

Teneo Excimer Laser Platform is a new laser assistance in situ keratomileusis for vision correction surgery for those who have myopia and myopic astigmatism.

Perfluorohexyloctane is the first and only treatment that targets tear evaporation to provide relief for dry eye disease

Preclinical studies and clinical trials have shown that both corticosteroids and VEGF inhibitors can be delivered as nanoparticles.

Faricimab is the first and only bispecific antibody granted FDA approval for treatment of the eye.

Pilocarpine improves near visual acuity by pupil modulation, leading to an increased ability to focus on nearby objects.

Teprotumumab (Tepezza) is a promising treatment for thyroid eye disease , although its precise mechanism of action remains incompletely characterized.

Cases address questions about how to relieve dry eyes.

The Mylight phase 3 trial confirmed that there was no clinically meaningful differences between aflibercept and its reference biologic, Eylea, for patients with wet macular degeneration.

Melphalan/hepatic delivery system (Hepzato Kit; Delcath Systems Inc) is currently the only liver-directed therapy approved by the FDA for the treatment of netastatic uveal melanoma and percutaneous hepatic perfusion.

Idiopathic intracranial hypertension was previously considered a rare condition, however, its prevalence is increasing in parallel with obesity in patient populations.